Saye Khoo spends much of his time researching Pharmacology, Internal medicine, Pharmacokinetics, Ritonavir and Immunology. He has included themes like Nevirapine, Efavirenz, Intracellular and Reverse-transcriptase inhibitor in his Pharmacology study. The various areas that Saye Khoo examines in his Internal medicine study include Gastroenterology, Endocrinology and Single-nucleotide polymorphism.
His Pharmacokinetics study integrates concerns from other disciplines, such as SLCO1B1 and Toxicity, Nephrotoxicity. His work deals with themes such as P-glycoprotein, Lopinavir, HIV Protease Inhibitor, Saquinavir and Atazanavir, which intersect with Ritonavir. His research integrates issues of Salvage therapy, Surrogate endpoint, Oncology and Antiretroviral therapy in his study of Immunology.
Saye Khoo mainly focuses on Pharmacology, Pharmacokinetics, Internal medicine, Ritonavir and Efavirenz. His specific area of interest is Pharmacology, where Saye Khoo studies Drug. Saye Khoo interconnects Pregnancy, Emtricitabine and Dosing in the investigation of issues within Pharmacokinetics.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Acquired immunodeficiency syndrome and Immunology. His studies in Immunology integrate themes in fields like Peripheral blood mononuclear cell, Antiretroviral therapy and Virology. His Ritonavir research is multidisciplinary, relying on both Darunavir, Lopinavir, Atazanavir and Saquinavir.
Internal medicine, Pharmacokinetics, Pharmacology, Dolutegravir and Efavirenz are his primary areas of study. His Internal medicine research includes elements of Gastroenterology, Artemether/lumefantrine, Lumefantrine and Standard treatment. His Pharmacokinetics research incorporates elements of Pharmacogenetics and Emtricitabine.
His biological study spans a wide range of topics, including Nitazoxanide and Long acting. His research on Dolutegravir also deals with topics like
His primary areas of investigation include Efavirenz, Internal medicine, Drug, Adverse effect and Pharmacokinetics. His Efavirenz research incorporates themes from Nevirapine and Darunavir. The concepts of his Internal medicine study are interwoven with issues in Malaria, Oncology and Standard treatment.
His work deals with themes such as Intensive care medicine, Lopinavir, Coronavirus disease 2019 and Ritonavir, which intersect with Drug. His study on Pharmacokinetics is covered under Pharmacology. When carried out as part of a general Pharmacology research project, his work on Cmax is frequently linked to work in Context, therefore connecting diverse disciplines of study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Sheena McCormack;David T. Dunn;Monica Desai;David I. Dolling.
The Lancet (2016)
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
B G Gazzard;Jane Anderson;Abdel Babiker;Marta Boffito.
Hiv Medicine (2005)
Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.
Jan C. De Jong;Anton G. Wermenbol;Marja W. Verweij-Uijterwaal;Kees W. Slaterus.
Journal of Clinical Microbiology (1999)
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito.
Hiv Medicine (2012)
HIV infection and stroke: current perspectives and future directions.
Laura A Benjamin;Laura A Benjamin;Alan Bryer;Hedley C A Emsley;Saye Khoo.
Lancet Neurology (2012)
Invasive aspergillosis in patients with AIDS.
Saye H. Khoo;David W. Denning.
Clinical Infectious Diseases (1994)
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Sonia Rodríguez-Nóvoa;Pablo Labarga;Vincent Soriano;Deirdre Egan.
Clinical Infectious Diseases (2009)
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).
Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito.
Hiv Medicine (2014)
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Andrew Hill;Saye Khoo;Joe Fortunak;Bryony Simmons.
Clinical Infectious Diseases (2014)
Controversies in HIV-associated neurocognitive disorders
Sam Nightingale;Alan Winston;Scott Letendre;Benedict D Michael;Benedict D Michael.
Lancet Neurology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: